Compare CVLG & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVLG | CSTL |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.7M | 722.8M |
| IPO Year | 1996 | 2019 |
| Metric | CVLG | CSTL |
|---|---|---|
| Price | $31.43 | $32.90 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $49.50 | $46.70 |
| AVG Volume (30 Days) | 189.5K | ★ 322.4K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $705,007,000.00 | $344,229,000.00 |
| Revenue This Year | $15.65 | $8.68 |
| Revenue Next Year | $6.72 | $12.08 |
| P/E Ratio | $69.14 | ★ N/A |
| Revenue Growth | ★ 5.12 | 3.66 |
| 52 Week Low | $18.00 | $17.72 |
| 52 Week High | $49.88 | $44.28 |
| Indicator | CVLG | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 43.17 |
| Support Level | $28.34 | $31.56 |
| Resistance Level | $35.71 | $34.23 |
| Average True Range (ATR) | 1.47 | 1.92 |
| MACD | 0.46 | -0.14 |
| Stochastic Oscillator | 50.08 | 9.47 |
Covenant Logistics Group Inc together with its wholly-owned subsidiaries, offers truckload transportation and freight brokerage services to customers throughout the continental United States. The company's reportable segments include Expedited, Dedicated Services, Managed Freight, and Warehousing. The expedited segment provides truckload services to customers with high service freight and delivery standards. Dedicated segment provides customers with committed truckload capacity over contracted periods with the goal of three to five years in length. The Managed Freight segment includes brokerage services and TMS. The warehousing segment provides day-to-day warehouse management services to customers who have chosen to outsource this function.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.